Fairvalue-Calculator Fairvalue-Calculator
EN DE

JiangXi Tianxin Pharmaceutical Co (603235) Fair Value & Analysis

Consumer Defensive · CN · Market cap 10.3B CNY

Price¥22.87
Fair Value¥18.70
Upside-18.2%
Quality95/100
Evidence: High Range ¥11.12 – ¥29.41

Fair value as of: Jun 24, 2026

Analysis

JiangXi Tianxin Pharmaceutical Co (603235) currently trades at ¥22.87, while our model-based Fair Value estimate is ¥18.70 — implying the stock looks roughly 18.2% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

JiangXi Tianxin Pharmaceutical Co., Ltd. produces and sells vitamins in China. The company offers products of vitamin B6, vitamin B1, Vitamin D3, pyridoxine hydrochloride CD grade, thiamine nitrate DC grade, folic acid, biotin, ascorbyl palmitate, vitamin E 500, a-acetyl-"-butyrolactone, and vitamin D3 for use as bulk pharmaceutical chemicals, API, food additives, and feed additives, as well as in other fields. JiangXi Tianxin Pharmaceutical Co., Ltd. was founded in 2004 and is based in Leping, China.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is JiangXi Tianxin Pharmaceutical Co (603235) undervalued?
As of Jun 24, 2026, our model estimates a fair value of ¥18.70 versus a price of ¥22.87 — about −18% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 603235?
Our 21-model fair value for JiangXi Tianxin Pharmaceutical Co is ¥18.70 (as of Jun 24, 2026), built from audited fundamentals. The current price is ¥22.87.
What is the quality score of 603235?
JiangXi Tianxin Pharmaceutical Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.